Anacor Pharmaceuticals has reported successful preliminary results from its Phase IIb trial of AN2728, used for the treatment of mild-to-moderate plaque-type psoriasis.

The randomised trial enrolled 68 subjects. Results showed that 26% of subjects in the AN2728 arm achieved Physicians Global Assessment success, compared to 18% in the vehicle arm.

Anacor Pharmaceuticals CEO David Perry said that the seven previous AN2728 trials, combined with the results from this trial, provide them with the data to prepare for a Phase II meeting with the US Food and Drug Administration and plan Phase III trials.

The drug-related adverse events observed included upper respiratory tract infection, contact dermatitis and nasopharyngitis.

AN2728, a boron-based small-molecule compound, reduces the production of inflammatory cytokines associated with psoriasis.